These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9468359)

  • 21. Monoamine oxidase inhibitors in South American hallucinogenic plants Part 2: Constituents of orally-active Myristicaceous hallucinogens.
    McKenna DJ; Towers GH; Abbott FS
    J Ethnopharmacol; 1984 Nov; 12(2):179-211. PubMed ID: 6521493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparison of altered states of consciousness induced by the hallucinogens (--)-delta9-trans-tetrahydrocannabinol (delta9-THC) and N,N-dimethyltryptamine (DMT) (author's transl)].
    Dittrich A; Bickel P; Schöpf J; Zimmer D
    Arch Psychiatr Nervenkr (1970); 1976 Dec; 223(1):77-87. PubMed ID: 1070948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. On the transmethylation hypothesis: stress, N,N-dimethyltryptamine, and positive symptoms of psychosis.
    Grammenos D; Barker SA
    J Neural Transm (Vienna); 2015 Jun; 122(6):733-9. PubMed ID: 25362533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hallucinogenic indoleamines: Preferential action upon presynaptic serotonin receptors.
    Aghajanian GK; Hailgler HJ
    Psychopharmacol Commun; 1975; 1(6):619-29. PubMed ID: 1063421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo long-term kinetics of radiolabeled n,n-dimethyltryptamine and tryptamine.
    Vitale AA; Pomilio AB; Cañellas CO; Vitale MG; Putz EM; Ciprian-Ollivier J
    J Nucl Med; 2011 Jun; 52(6):970-7. PubMed ID: 21622895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of the phenomenology of hallucinogens and schizophrenia from some autobiographical accounts.
    Kleinman JE; Gillin JC; Wyatt RJ
    Schizophr Bull; 1977; 3(4):560-86. PubMed ID: 271353
    [No Abstract]   [Full Text] [Related]  

  • 27. Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers.
    Riba J; Rodríguez-Fornells A; Urbano G; Morte A; Antonijoan R; Montero M; Callaway JC; Barbanoj MJ
    Psychopharmacology (Berl); 2001 Feb; 154(1):85-95. PubMed ID: 11292011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ritualistic Use of Ayahuasca versus Street Use of Similar Substances Seized by the Police: A Key Factor Involved in the Potential for Intoxications and Overdose?
    Lanaro R; Calemi DB; Togni LR; Costa JL; Yonamine M; Cazenave Sde O; Linardi A
    J Psychoactive Drugs; 2015; 47(2):132-9. PubMed ID: 25950593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potentially hallucinogenic 5-hydroxytryptamine receptor ligands bufotenine and dimethyltryptamine in blood and tissues.
    Kärkkäinen J; Forsström T; Tornaeus J; Wähälä K; Kiuru P; Honkanen A; Stenman UH; Turpeinen U; Hesso A
    Scand J Clin Lab Invest; 2005; 65(3):189-99. PubMed ID: 16095048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DMT alters cortical travelling waves.
    Alamia A; Timmermann C; Nutt DJ; VanRullen R; Carhart-Harris RL
    Elife; 2020 Oct; 9():. PubMed ID: 33043883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Basics of the medical use of ayahuasca: physiology of dimethyltryptamine.
    Ede F; Attila K; Attila S; Csaba F; Csaba M
    Lege Artis Med; 2016; 26(9-10):413. PubMed ID: 29537778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT(1A) and 5-HT(2A) receptors.
    Riga MS; Bortolozzi A; Campa L; Artigas F; Celada P
    Neuropharmacology; 2016 Feb; 101():370-8. PubMed ID: 26477571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hallucinogens as discriminative stimuli: a comparison of 4-OMe DMT and 5-OMe DMT with their methythio counterparts.
    Glennon RA; Young R; Benington F; Morin RD
    Life Sci; 1982 Feb; 30(5):465-7. PubMed ID: 6801410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness.
    Hamill J; Hallak J; Dursun SM; Baker G
    Curr Neuropharmacol; 2019; 17(2):108-128. PubMed ID: 29366418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urinary excretion of n,n-dimethylated tryptamines in chronic schizophrenia. A review of the present status of the hypothesis.
    Huszka L; Zabek DH; Doust JW
    Can Psychiatr Assoc J; 1976 Dec; 21(8):541-6. PubMed ID: 1071579
    [No Abstract]   [Full Text] [Related]  

  • 36. The hallucinogenic world of tryptamines: an updated review.
    Araújo AM; Carvalho F; Bastos Mde L; Guedes de Pinho P; Carvalho M
    Arch Toxicol; 2015 Aug; 89(8):1151-73. PubMed ID: 25877327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developments in harmine pharmacology--implications for ayahuasca use and drug-dependence treatment.
    Brierley DI; Davidson C
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Dec; 39(2):263-72. PubMed ID: 22691716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca.
    McKenna D; Riba J
    Curr Top Behav Neurosci; 2018; 36():283-311. PubMed ID: 28401525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies.
    Dos Santos RG; Bouso JC; Hallak JEC
    Ther Adv Psychopharmacol; 2017 Apr; 7(4):141-157. PubMed ID: 28540034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans.
    Valle M; Maqueda AE; Rabella M; Rodríguez-Pujadas A; Antonijoan RM; Romero S; Alonso JF; Mañanas MÀ; Barker S; Friedlander P; Feilding A; Riba J
    Eur Neuropsychopharmacol; 2016 Jul; 26(7):1161-75. PubMed ID: 27039035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.